HCW Biologics Licenses TRBC Asset to China JV Trimmune

The latest update is out from HCW Biologics ( (HCWB) ).

On February 13, 2026, HCW Biologics and China-based WY Biotech announced an exclusive worldwide license agreement granting newly formed Beijing Trimmune Biotech rights to develop and commercialize in vivo applications of HCW11-006, a preclinical TRBC-platform molecule, with an added option on Greater China rights for clinical-stage HCW9302. The structure positions Trimmune, backed by CITIC Medical Fund and TigerYeah Capital Fund of TigerMed, as the operating licensee focused on cancer-related indications.

The parties closed a first round of financing for Trimmune, under which HCW Biologics receives a $3.5 million upfront cash license fee, paid in two tranches starting February 13, 2026, plus a minority co-founder equity stake currently valued at about $3.5 million. HCW Biologics is also eligible for milestone payments, double-digit royalties on future sales, and a share of proceeds from any future transactions involving HCW11-006, creating a capital-efficient way to advance the asset.

Trimmune plans to initiate a Phase 1 trial in China to evaluate HCW11-006 in solid tumors in the first half of 2027, funding all Phase 1 costs and giving HCW Biologics access to early clinical data without bearing development expenses. Management expects that strong preclinical results and a dual China-U.S. development pathway could generate significant interest from multinational pharmaceutical companies and broaden options for future partnerships.

The agreement also grants HCW Biologics a payment-free, milestone-free, royalty-free option to recapture all rights to HCW11-006 for in vivo applications in the Americas after completion of the Chinese Phase 1 study, at which point the companies would co-develop the drug and coordinate global business development. This structure allows HCW Biologics to share in upside via equity and profit-sharing while limiting near-term cash burn, potentially strengthening its financial position and de-risking advancement of its TRBC platform in oncology.

The most recent analyst rating on (HCWB) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on HCW Biologics stock, see the HCWB Stock Forecast page.

Spark’s Take on HCWB Stock

According to Spark, TipRanks’ AI Analyst, HCWB is a Neutral.

The score is held down primarily by very weak financial performance (sharp revenue decline, negative gross profit in TTM, persistent cash burn, and negative equity). Technicals also remain unfavorable with price below key longer-term moving averages and negative MACD. Offsetting factors are limited to positive corporate developments (financing/liability settlement to bolster equity and a Phase 1 trial start), which improve near-term positioning but do not yet change the fundamental risk profile.

To see Spark’s full report on HCWB stock, click here.

More about HCW Biologics

HCW Biologics Inc. is a U.S.-based, clinical-stage biopharmaceutical company developing proprietary immunotherapies to treat diseases driven by chronic inflammation, particularly age-related and senescence-associated conditions. Its pipeline, built on the TOBI and TRBC platforms, targets oncology, autoimmune and other inflammatory diseases, with lead candidate HCW9302 in a Phase 1 trial for an autoimmune disorder.

The company’s TRBC drug discovery platform enables construction of multi-functional immune cell stimulators, second-generation checkpoint inhibitors and multi-specific targeting fusions designed to activate immune responses while directing them toward cancerous or infected cells. HCW Biologics has created more than 50 TRBC-based molecules and operates two licensing programs granting exclusive rights to select proprietary assets.

Average Trading Volume: 94,746

Technical Sentiment Signal: Sell

Current Market Cap: $3.25M

Learn more about HCWB stock on TipRanks’ Stock Analysis page.